# TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors

> **NCT05650580** · PHASE1 · RECRUITING · sponsor: **Tarapeutics Science Inc.** · enrollment: 26 (estimated)

## Conditions studied

- Non-Hodgkin's Lymphoma, Relapsed
- Non-Hodgkin's Lymphoma Refractory
- Advanced Solid Tumor

## Interventions

- **DRUG:** TR115

## Key facts

- **NCT ID:** NCT05650580
- **Lead sponsor:** Tarapeutics Science Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-23
- **Primary completion:** 2025-07-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2024-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05650580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05650580, "TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05650580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*